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Abstract
We propose a flexible joint longitudinal-survival framework to examine the as-
sociation between longitudinally collected biomarkers and a time-to-event endpoint.
More specifically, we use our method for analyzing the survival outcome of end-stage
renal disease patients with time-varying serum albumin measurements. Our pro-
posed method is robust to common parametric assumptions in that it avoids explicit
distributional assumptions on longitudinal measures and allows for subject-specific
baseline hazard in the survival component. Fully joint estimation is performed to
account for the uncertainty in the estimated longitudinal biomarkers included in the
survival model.
Keywords: Bayesian nonparameterics; Gaussian processes; Dirchilet process mixture mod-
els; Longitudinal data analysis; Proportional hazard models
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1 Introduction
In this paper, we propose a flexible joint longitudinal-survival framework for quantifying
the association between longitudinally measured biomarkers (e.g., serum albumin) and
time-to-death among end-stage renal disease (ESRD) patients. ESRD is a condition where
the filtration performed by the kidneys has been reduced to a point at which life can no
longer adequately be sustained. According to data from the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) over 850,000 persons in the United States are
being treated for ESRD and many more suffer from early stage chronic kidney disease. The
standard of care for adult ESRD patients that do not have access to a viable transplant is
hemodialysis. Hemodialysis patients experience extremely high mortality rates. Multiple
epidemiologic studies have shown that indices of protein-energy malnutrition (PEM) are a
strong predictor of total mortality among hemodialysis patients (Fung et al., 2002; Wong
et al., 2002). Serum albumin, a protein biomarker and surrogate for nutritional status, is
among the indices of PEM that have been associated with mortality. Fung et al. (2002)
found that among hemodialysis subjects, baseline albumin level and the slope of albumin
over time were independent risk factors for mortality, suggesting that the low albumin
level is not simply a consequence of co-morbidities associated with dialysis but may be
a precursor. This analysis did not consider other potential characteristics of the within-
subject changes in serum albumin that may also be associated with mortality in this high
risk population. It is natural to hypothesize that high within-subject variability in serum
albumin measured over time may also be indicative of increased mortality. That is, non-
linear patterns or high instability around a patient’s first-order trend is likely an indication
of nutritional instability (possibly due to inadequate dialyzing) and hence may be a risk
factor for morbidity and mortality. While this association is plausible, it has not been
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considered in the literature to the best of our knowledge. The reason for this may be due
to the difficulty in summarizing and efficiently estimating within-subject variability around
a specified mean model using standard statistical methodology. However, if the hypothesis
were established, this summary measure would provide nephrologists with an additional
biomarker to monitor ESRD patients and potentially decrease the risk of mortality in these
patients. This is one of the main objectives of our study. To this end, we propose a flexible
joint longitudinal-survival model.
Flexibility in our joint model is achieved in the longitudinal component via the use
of a Gaussian process prior with a parameter that captures within-subject volatility in
time-varying biomarkers. The survival component of our proposed models quantifies the
association between the longitudinally measured biomarkers and the risk of mortality us-
ing a Dirichlet process mixture of Weibull distributions. The clustering mechanism of the
Dirichlet process provides a framework for borrowing information when estimating subject-
specific baseline hazards in the survival component. Estimation for the longitudinal and
survival parameters is carried out simultaneously via Bayesian parameter posterior sam-
pling approach.
In contrast to most competing models, our proposed method provides the following ad-
vantages: 1) it avoids relying on restrictive parametric assumptions; 2) it properly accounts
for variability in longitudinal measures; 3) it provides a natural framework to capture the
association of both first and second moments of the distribution of the longitudinal co-
variate with survival; and 4) its underlying mechanism for clustering patients can help
clinicians to design more personalized treatments.
In what follows, we provide an overview of some related methods and discuss the specific
dataset used in our research.
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1.1 Some Related Methods
Survival analysis often involves evaluating effects of longitudinally measured biomarkers
on mortality. When longitudinal measures are sparsely collected, incomplete, or prone to
measurement error, including them directly as a traditional time-varying covariate in a
survival model may lead to biased regression estimates (Prentice, 1982). To address this
issue, one could apply a two-stage method, where the first stage consists of modeling the
longitudinal components via a mixed-effects model, and in the second stage, the modeled
values or their summaries (e.g., first-order trends) are included in a survival model (Dafni
and Tsiatis, 1998; Tsiatis et al., 1995). Standard approaches for analyzing longitudinal
covariates include frequentist mixed effects models (Verbeke and Molenberghs, 2000; Pin-
heiro and Bates, 2000) and Bayesian hierarchical models (Christensen et al., 2010; Gelman
et al., 2003). In general, these approaches parameterize the population mean model as a
function of potentially time-varying covariates, subject-specific deviations from the popula-
tion mean via random effects, and residual variability by subject level variance-covariance
matrices that generally account for serial auto-correlation. More recently, several authors
have proposed Gaussian process (GP) models as an alternative to more standard longitudi-
nal regression methods since they easily allow for flexible model specification in a coherent
probabilistic framework (Shi et al., 2007; Liu et al., 2010).
Two-stage methods in general fail to account for uncertainty in the estimated longitudi-
nal summary measures. To overcome this issue, several joint longitudinal-survival models
have been proposed (Prentice, 1982; Bycott and Taylor, 1998; Hanson et al., 2011; Wang
and Taylor, 2001; Faucett and Thomas, 1996; Brown and Ibrahim, 2003; Wulfsohn and
Tsiatis, 1997; Song et al., 2002; Law et al., 2002). These models account for uncertainty
in longitudinal measures by modeling them simultaneously with the survival outcome.
However, most existing joint models still rely on multiple restrictive parametric and semi-
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parametric assumptions and generally focus only on associating the first moment of the
distribution of the longitudinal covariate with survival. In this paper, we address these
issues by developing a flexible joint longitudinal-survival framework that avoids simple dis-
tributional assumptions on longitudinal measures and allow for subject-specific baseline
hazard in modeling the survival outcome.
1.2 United States Renal Data System
The specific dataset we consider in this study is obtained from the United States Renal
Data System (USRDS). The USRDS collects and maintains demographic, treatment, and
mortality on all Medicare covered ESRD patients undergoing renal replacement therapy.
Details of the USRDS are described elsewhere (USRD, 2010). In addition to its standard
data collection, the USRDS has periodically conducted individual special studies. Termed
the Dialysis Morbidity and Mortality Studies (DMMS), these specialized studies were car-
ried out to obtain more specific information on smaller samples of ESRD patients. Four
DMMS studies were conducted in waves in the 1990s. The first of these studies, DMMS
Wave 1 (DMMS-1), included a nutritional sub-cohort of N=2,613 hemodialysis patients in
which monthly and bimonthly PEM index measures, including serum albumin, were longi-
tudinally collected over 18 months. Given the longitudinal nature of DMMS-1, the study
is ideal for estimating within-subject changes in serum albumin. In addition, because the
USRDS collects and maintains data on the time and cause of death, this study can also be
used to assess whether derived characteristics of within-subject changes in serum albumin
are associated with mortality.
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2 Methodology
In this section, we provide the details of our proposed joint models for a longitudinal covari-
ate, X, and a survival outcome, Y . Throughout this section, we consider n independent
subjects where li longitudinal measurements, Xij, are obtained for subject i at time points
tij, j = 1, . . . , li. Also, associated with each subject, there is an observed survival time,
Yi ≡ min{Ti, Ci} and event indicator δi ≡ 1[Yi=Ei], where Ti and Ci denote the true event
and censoring time for subject i, respectively. Further, we make the common assumption
that Ci is independent of Ti for all i, i = 1, . . . , n.
2.1 The Joint Model
Being interested in estimating the effect of longitudinal measures on survival outcomes,
for specifying the joint model likelihood we took a similar approach as Brown and Ibrahim
(2003), where we define the contribution of each subject to the joint model likelihood as the
multiplication of the likelihood function of the longitudinal measures for that subject and
her/his time-to-event likelihood that is conditioned on her/his longitudinal measures. Let
f
(i)
L , f
(i)
S|L, and f
(i)
L,S denote the longitudinal likelihood contribution, the conditional survival
likelihood contribution, and the joint likelihood contribution for subject i. One can write
the joint longitudinal-survival likelihood function as
fL,S =
n∏
i=1
f
(i)
L,S =
n∏
i=1
(
f
(i)
L × f (i)S|L
)
. (1)
2.2 Longitudinal Component
We motivate the development of the Gaussian process model for the longitudinal biomarker
by first considering the following simple linear model for estimating the trend in the
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biomarker for a single subject i with an li× 1 vector of measure biomarkers of Xi which is
of the form
Xi =

Xi(ti1)
Xi(ti2)
...
Xi(tili)
 ,
where
Xi|β(L)i0 ∼ N(β(L)i0 ,Σi).
with β
(L)
i0 as the subject-specific intercept, β
(L)
i0 is vector of repeated β
(L)
i0 value that is of
size li × 1, and Σi = σ2Ili×li .
By adding a stochastic component that is indexed by time in the model, one can extend
the model to capture non-linear patterns over time. Specifically, we consider a stochastic
vector, W , that is a realization from a Gaussian process prior, W (t) with mean zero
and covariance function C(t, t′). Thus for subject i, Wi ∼ Nli(0,Cli×li), where Wi =
(Wti1 , . . . ,Wtili )
′ and the (j, j′) element of Cli×li is given by C(tij, tij′),j, j
′ ∈ {1, . . . , li}.
We characterize the covariance function, Cli×li , using the following squared exponential
form
Cli×li(j, j
′) = κi2e−ρ
2(tij−tij′ )2 .
In this setting, the hyperparameter ρ2 controls the correlation length, and κ2 controls
the height of oscillations (Banerjee et al., 2014), and tij and tij′ are two different time points.
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For notational simplicity, we define Ki = e
−ρ2(tij−tij′ )2 ; j, j′ ∈ {1, . . . , li}, and re-write our
longitudinal model as
Xi|β(L)i0 , κi2, ρ2, σ2 ∼ N(β(L)i0 , κi2Ki + σ2Ili×li),
where σ2 is assumed to be common across all subjects. The correlation length parameter
ρ2 controls the maximum distance in time between two time-dependent measurements
to be still correlated. This distance for GP models is often called the practical range.
Diggle et al. (2007) defined the practical range for GP as the distance in time between two
time-dependent measurements where the correlation between those two measurements is
0.05. With the squared exponential covariance function, that practical range distance is
of the form
√
3/ρ2. At a ρ2 = 0.1, the practical range distance is 5.7 months which is a
reasonable range for the real data on end-stage renal disease patients that was obtained
from the USRDS. Hence, we fix ρ2 to 0.1, where this value was obtained from the real data
on end stage renal disease patients data. By defining our model in this way, subject-specific
parameter κ2i will have the role of capturing within-subject volatility of the longitudinal
measures. In the context of the motivating USRDS example, κ2i can be of primary scientific
interest as it reflects the within-subject volatility (Figure 1) in serum albumin over time,
which is hypothesized to be negatively correlated with longer survival time (Holsclaw et al,
2014).
We specify the longitudinal component of our joint model to have a likelihood of the
form
Xi|Wi, β(L)i0 , κi2, ρ2, σ2 ∼ N(β(L)i0 +Wi, σ2Ili×li), (2)
where Xi is a vector of longitudinal measures on subject i, Wi is a Gaussian process
stochastic vector, β
(L)
i0 is subject specific intercept for subject i, κi
2 is a subject-specific
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Figure 1: With a fixed correlation length parameter ρ2, κ2 parameter captures volatility in
Gaussian process models with the squared exponential covariance function. In each plot,
ten random realizations of the Gaussian process were selected, where the plot to the left
has a κ2 parameter of 0.01, the plot in the middle has a κ2 value of 0.5, and the plot to the
right has a κ2 value of 1.0. In all plots, correlation length ρ2 is fixed to 0.1 .
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measure of volatility for subject i, ρ2 is a fixed correlation length, σ2 is a measurement
error that is shared across all subjects, and finally Ili×li represents the identity matrix of
size li where li is the number of longitudinal measures on subject i. The Gaussian process
stochastic vector Wi is distributed Gaussian process as
Wi|κi2, ti ind∼ GPmi(~0, κi2Ki), (3)
where ti is a vector of the time points at which longitudinal measures on subject i were
collected and Ki = e
−ρ2(tij−tij′ )2 , with tij and tij′ are the jth and j′
th element of the time
vector ti. We assume a Normal prior on the subject-specific random intercepts β
(L)
i0 that
is of the form
β
(L)
i0
i.i.d∼ N(µ
β
(L)
0
, σ2βL0
), (4)
where µ
β
(L)
0
and σ2
βL0
are prior mean and prior variance respectively. Ki, where i ∈
{1, . . . , n} with n as the number of subjects in the study, are assumed to have a log-Normal
prior with the prior mean µκ2 and the prior variance σκ2 that is of the form
κi
2 i.i.d∼ log-Normal(µκ2 , σ2κ2). (5)
The correlation length ρ2 is assumed to be fixed and known in our model. Finally, the
measurement error σ2 is assumed to have a log-Normal prior of the form
σ2 ∼ log-Normal(µσ2 , σ2σ2), (6)
where µσ2 and σσ2 are the prior mean and the prior variance respectively.
2.3 Survival Component
In order to quantify the association between a longitudinal biomarker and a time-to-event
outcome, we define our survival component by using a multiplicative hazard model with
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the general form of
λ(Ti|Zi(s),Zi(L)) = λ0(Ti)exp{ζ(s)Zi(s) + ζ(L)Zi(L)(t)}, (7)
where Zi
(s) is a vector of baseline covariates, Zi
(L) is a vector of longitudinal covariates
from the longitudinal component of the model, λ0(Ti) denotes the baseline hazard function,
and ζ(S) and ζ(L) are regression coefficients for the baseline survival covariates and the
longitudinal covariates, respectively.
We consider a Weibull distribution for the survival component to allow for log-linear
changes in the baseline hazard function over time. Thus we assume
Ti ∼ Weibull(τ, λi), (8)
where Ti is the survival time, τ is the shape parameter of the Weibull distribution, and
exp{λi} is the the scale parameter of the Weibull distribution. One can write the density
function for the Weibull distribution above for the random variable Ti as
f(Ti|τ, λi) = τTiτ−1exp
(
λi − exp(λi)Tiτ
)
. (9)
In this case, the Weibull distribution is available in closed form providing greater com-
putational efficiency. Under this parameterization, covariates can be incorporated into the
model by defining λi = ζ
(s)Zi
(s) + ζ(L)Zi
(L). In particular, we specify our model as
Ti|τ, ζ(s), ζ(L),Zi(s),Zi(L) ∼ Weibull(τ, λi = β(s)i0 + ζ(s)Zi(s) + ζ(L)Zi(L)), (10)
where τ is a common shape parameter shared across all subjects. β
(s)
i0 is a subject specific
coefficient in the model which allows for a subject-specific baseline hazard. Zi
(s) and ζ(s)
are baseline covariates and their corresponding coefficients, respectively. Finally, Zi
(L)
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and ζ(L) are coefficients linking the longitudinal parameters of interest to the hazard for
mortality.
In order to avoid an explicit distributional assumption for the survival times, we specify
our survival model as an infinite mixture of Weibull distributions that is mixed on the β
(s)
i0
parameter. In particular, we use the Dirichlet process mixture of Weibull distributions that
is defined as
β
(s)
i0 |µi, σ2β(s)0 ∼ N(µi, σ
2
β
(s)
0
), (11)
µi|G ∼ G, (12)
G ∼ DP(α(S), G0), (13)
where σ2
β
(s)
0
is a fixed parameter, µi is a subject-specific mean parameter from a distribution
G with a DP prior, α(S) is the concentration parameter of the DP and G0 is the base
distribution. By using the Dirichlet process prior on the distribution of β
(s)
i0 , we allow
patients with similar baseline hazards to cluster together which subsequently provides a
stronger likelihood to estimate the baseline hazards. For other covariates in the model, we
assume a multivariate normal prior of the form(
ζ(s), ζ(L)
) ∼ MVN(0, σ02I),
where σ0
2 is a prior variance and I is an identity matrix.
The shared scale parameter τ is considered to have a Log-Normal prior of the form
τ ∼ log-Normal(aτ , bτ ),
where aτ and bτ are fixed prior location and prior scale parameters, respectively.
Finally, we assume that information about the concentration parameter of the Dirichlet
process can be specified with the prior
α(S) ∼ Γ(a(S)α , b(S)α ),
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where a
(S)
α and b
(S)
α are fixed prior shape and prior scale parameters, respectively.
2.4 Linking the Two Components
The proposed modeling framework easily allows for associating multiple summaries of the
longitudinal biomarker with the time-to-event outcome. Here we consider three alternative
models that incorporate various summary measures of the longitudinal trajectory that are
easily and flexibly estimated using the GP model presented in Section 2.2:
Model I: directly modeling longitudinal outcome at each event time t as a covariate
in the survival model:
Zi
(L) = X i(t)
Model II: modeling both the value of the longitudinal covariate and also the average
rate at which the biomarker changes for each subject. We define this average rate as
a weighted area under the derivative curve of the biomarker trajectory
Zi
(L) =
(
Xi(t), X
′
AUC
τ0−τ1)
where, X ′AUC
τ0−τ1 =
∫ τ1
τ0
Q(u)X ′(u)du
where X ′AUC
τ0−τ1 is a time-dependent covariate that is a weighted average of the
derivative of the biomarker trajectory, that is denoted by X ′(u) from τ0 to τ1 where
τ1 is the time of death for each subject. This average area under the derivative curve
can be a weighted average with weights Q(u).
Model III: modeling summary measures of the longitudinal trajectory. Motivated
by the scientific question of interest, in this paper we consider random intercepts
and subject-specific volatility as summary measures of interest:
Zi
(L) =
(
β
(L)
0i , κ
2
i
)
13
Below, we will explain these three models in more detail.
2.4.1 Model I: a Survival model with Longitudinal Biomarker at event time
as a covariate
This model quantifies the association between a longitudinal biomarker of interest and
the time-to-event outcome by directly adjusting for the biomarker measured values in the
survival component. While usually biomarkers are measured on a discrete lab-visit basis,
the event of interest happens on a continuous basis. While common frequentist models use
the so-called last-observation-carried forward (LOCF) technique where the biomarker value
at each even time is assumed to be the same as the last measured value for that biomarker,
our joint flexible longitudinal-survival model provides a proper imputation method for
the biomarker values at each individual’s event time. In particular, in each iteration of
the MCMC, given the sampled parameters for each individual and by using the flexible
Gaussian process prior, there exists posterior trajectories of biomarker for that individual.
Our method, then, considers the posterior mean of those trajectories as the proposed
trajectory for that individual’s biomarker values over time at that iteration. The trajectory,
then, can be used to impute time-dependent biomarker covariate value inside the survival
component. To be more specific, consider the longitudinal biomarker Xi of the form
Xi|β(L)i0 , κi2, ρ2, σ2 ∼ N(β(L)i0 , κi2Ki + σ2Ili×li),
where β
(L)
i0 is subject-specific random intercept for subject i, β
(L)
i0 is a vector of repeated
subject-specific intercept β
(L)
i0 that is of size li×1, κi2 is subject-specific measure of volatility
in the longitudinal biomarker for individual i, ρ2 is a fixed measure of correlation length,
σ2 is the measurement error shared across all subjects, Ki is a an li× li matrix with it’s jj′
element as Kijj′ = e
−ρ2(tij−tij′ )2 where li is the number of longitudinal biomarker measures
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on subject i, and Ili×li is the identity matrix.
For a new time-point t∗, predicted albumin biomarker for individual i is X∗ and can be
written as
X∗|Xi, t, t∗ ∼ N(µ∗,Σ∗),
where the conditional posterior mean µ∗ is
µ∗ = βLi0 +K(t
∗, t)KX−1(Xi − β(L)i0 ), (14)
and the conditional posterior variance Σ∗ is
Σ∗ = K(t∗, t∗)−K(t∗, t)KX−1K(t∗, t)′, (15)
where K(t∗, t) is defined as
K(t∗, t) = κi2e−ρ
2(t∗−t)2 , (16)
and K−1X is defined as
K−1X = (K(t, t) + σ
2Ili×li)
−1. (17)
In order to relate the biomarker value at each time point t to the risk of the event of interest
at that time point, ”death”, we form the survival component of the model as
Ti|τ, ζ(s), ζXi ∼ Weibull(τ, λi = β(s)i0 + ζ(s)Zi(s) + ζXiXi(t)),
where Ti is the survival time, τ is the shape parameter of the Weibull distribution, ζ
(s) is
a vector of coefficients relating baseline survival covariates to the risk of the occurrence of
the event of interest, ζXi is the coefficient that relates the biomarker value at time t and
the risk of ”death” at that time point, λi is the log of the scale parameter in the Weibull
distribution, β
(s)
i0 is the subject-specific baseline hazard for subject i, Zi
(s) is a vector of
survival coefficients, and Xi(t) is the biomarker value at time t.
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2.4.2 Model II: A Survival model with covariates of Biomarker Value and the
Derivative of its Trajectory at event Time
In order to get more precision in quantifying the association between the biomarker value
at time t and the risk of death, we can extend our proposed model-I by including a measure
of the average slope of the biomarker over time. In particular, we define this average slope
from time τ0 to τ1 as the area under the derivative of the trajectory curve of the biomarker
from τ0 to τ1. More generally, this area under the curve can be a weighted sum where
weights are chosen according to the scientific question of interest. One may hypothesize
that the area under the derivative curve that are closer to the event time should be weighted
higher compared to the areas that are farther away from time point t. In general, we define
a weighted area under the derivative curve of the form
X ′AUC
τ0−τ1 =
∫ τ1
τ0
Q(u)X ′(u)du,
where τ0 and τ1 are arbitrary time points chosen according to the scientific question of
interest, Q(t) is a weight, and X ′(t) represents the derivative of the biomarker over time.
In particular, we consider two weighted approaches, where one assumes an equal weight of
the form
Q(t) =
1
τ1 − τ0 ,
and another weight of the form
Q(t) =
1, if t = Ti0, otherwise.
Under the first weighting scheme, X ′AUC will be the area under the derivative with equal
weights, whereas the second weighting scheme leads to the pointwise derivative value at
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the the event time. Under this model, the survival component of our joint model will now
include two longitudinal covariates, one the biomarker value Xi(t), and another the average
derivative of the biomarker trajectory, X ′AUC .
The derivative of the Gaussian process is still a Gaussian process with the same hyper
parameters ρ2 and κ2. Therefore, using the same idea of modeling the trajectory of the
biomarker, we can also model the derivative of that trajectory. In our model-I, we proposed
using the posterior mean of all plausible biomarker trajectories as the proposed trajectory
for each subject in order to impute biomarker values at any time point t inside the survival
component of the model. Similarly, we propose using the posterior mean of all plausible
derivative trajectories for each subject in order to compute the average derivative up until
time t. Given the fact that differentiation is a linear operation, one can easily compute the
posterior mean of the derivative curve by simply switching the order of the differentiation
and the expectation as
E(X ′i(t)) = E(
∂Xi(t)
∂t
)
=
∂
(
E(Xi(t))
)
∂t
.
Hence, by using Formula (14) and by taking the derivative of the posterior mean trajec-
tory of the biomarker with respect to time t∗, the posterior mean of the derivative of the
biomarker trajectory is of the form
∂
(
E(Xi(t
∗))
)
∂t∗
= −2ρ2(t∗ − t)′(K(t∗, t)KX−1(Xi − β(L)i0 )), (18)
where E
(
Xi(t
∗)
)
denotes the posterior mean of the biomarker trajectory as a function of
time t∗, ρ2 is the correlation length, t∗ is the time-point at which we desire to impute the
biomarker value and the average derivative of the biomarker trajectory, β
(L)
i0 is subject-
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specific random intercept, K(t∗, t) is defined as
K(t∗, t) = κi2e−ρ
2(t∗−t)2 , (19)
and K−1X is defined as
K−1X = (K(t, t) + σ
2Ili×li)
−1. (20)
Given the the biomarker value Xi(t) and the average derivative value X
′
AUC,i(t), the survival
component of our proposed joint model is of the from
Ti|τ, ζ(s), ζXi , ζX′i ∼ Weibull(τ, λi = β
(s)
i0 + ζ
(s)Zi
(s) + ζXiXi(t) + ζX′iX
′
AUC,i(t)),
where Ti is the survival time, τ is the shape parameter of the Weibull distribution, ζ
(s) is
a vector of coefficients relating baseline survival covariates to the risk of the occurrence of
the event of interest, ζXi is the coefficient that relates the biomarker value at time t and the
risk of ”death” at that time point, ζX′i is the coefficient that relates the average derivative
of the biomarker trajectory up until t and the risk of ”death” at that time point, λi is the
log of the scale parameter in the Weibull distribution, β
(s)
i0 is the subject-specific baseline
hazard for subject i, and Zi
(s) is a vector of survival coefficients.
2.4.3 Model III: A Survival Model with Summary Measures of the Longitu-
dinal Curve as Covariates
One may choose to characterize longitudinal trajectories with summary measures instead of
using the actual biomarker value. In specific, the longitudinal model we proposed provides
a natural parameter for describing the within-subject volatility. Given the nature of our
proposed longitudinal model, one can summarize the longitudinal trajectory of biomarker
by using β
(L)
0i as a measure of subject-specific intercept of longitudinal biomarker as well
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as κ2i as a measure of volatility of those trajectories. The survival component of the model
is then of the form
Ti|τ, β(s)i0 , ζ(s), ζβ0i (L), ζκi2 (L) ∼ Weibull(τ, λi = β(s)i0 + ζ(s)Zi(s) + ζβ0i (L)β0i(L) + ζκi2 (L)κi2),
where Ti is the survival time, τ is the shape parameter of the Weibull distribution, ζ
(s)
is a vector of coefficients relating baseline survival covariates to the risk of the occurrence
of the event of interest, ζβ0i
(L) is the coefficient that relates the subject specific random
intercept β0i
(L) and the risk of ”death”, ζκi2
(L) is the coefficient that relates the subject-
specific measure of volatility of the biomarker measure and the risk of ”death”, λi is the
log of the scale parameter in the Weibull distribution, β
(s)
i0 is the subject-specific baseline
hazard for subject i, and Zi
(s) is a vector of survival coefficients.
3 Posterior Distribution
Consider the joint longitudinal-survival likelihood function, fL,S, introduced in equation
1. Let ω be a vector of all model parameters with the joint prior distribution pi(ω). The
posterior distribution of the parameter vector ω can be written as
pi(ω|X,Y ) ∝ fL,S × pi(ω), (21)
where X and Y denote longitudinal and time-to-event data respectively, and fL,S is the
joint model likelihood function (equation 1).
The posterior distribution of the parameters in our proposed joint model is not available
in closed form. Hence, samples from the posterior distribution of the model parameters are
obtained via Markov Chain Monte Carlo (MCMC) methods. We use a hybrid sampling
technique where in each iteration of the MCMC, we first sample subject-specific frailty
19
terms in the survival model using Neal’s algorithm 8. Then given the sampled frailty
terms, we use the Hamiltonian Monte Carlo (Neal, 2011) to draw samples from the posterior
distribution. Prior distributions on parameters of the joint model were explained in details
in Sections 2.2 and 2.3, and we assume independence among model parameters in the prior
(ie. pi(ω) is the product of the prior components specified previously). We provide further
detail on less standard techniques for sampling from the posterior distribution when using
a GP prior and issues in evaluating the survival portion of the likelihood function when
time-varying covariates are incorporated into the model.
3.1 Evaluation of the Longitudinal Likelihood
The longitudinal component of our model uses the Gaussian process technique. Gaussian
process models are typically computationally challenging to fit because in each iteration
of the MCMC the evaluation of the log-posterior probability becomes computationally
challenging as the number of measurements increases. In particular, consider our proposed
longitudinal model introduced in Section 2.2 where
Xi|Wi, β(L)i0 , κi2, ρ2, σ2 ∼ N(β(L)i0 +Wi, σ2Ili×li),
Wi|κi2, ti ∼ GPmi(~0, κi2Ki),
with Xi denoting a vector of longitudinal measures on subject i, W i a Gaussian process
stochastic vector, β
(L)
i0 a subject specific intercept for subject i, κi
2 a subject-specific mea-
sure of volatility for subject i, ρ2 a fixed correlation length, σ2 a measurement error that is
shared across all subjects, Ili×li denoting the identity matrix of size li with li the number
of longitudinal measures on subject i, ti a vector of the time points at which longitudinal
measures on subject i were collected, and Ki = e
−ρ2(tij−tij′ )2 , where tij and tij′ are the jth
and j′th element of the time vector ti.
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In order to sample from the posterior distribution of κi
2 and σ2 parameters, one can
consider a marginal distribution of the following form
Xi|β(L)i0 , κi2, ρ2, σ2 ∼ N(β(L)i0 , κi2Ki + σ2Ili×li) (22)
The marginal distribution above has log-density of the form
log(f(Xi|β(L)i0 , κi2, ρ2, σ2)) = constant
− 1
2
log|κi2Ki + σ2Ili×li | (23)
− 1
2
(Xi − β(L)i0 )T (κi2Ki + σ2Ili×li)−1(Xi − β(L)i0 ),
that is the log contribution of subject i to the longitudinal likelihood ( i.e. log(f
(i)
L ) ).
sampling from the posterior distribution of κi
2 and σ2 requires evaluation of the log-
density in equation (23) that involves evaluation of the determinant and the computation of
the inverse of the covariance matrix at each iteration of the MCMC. This process requires
O(li
2) memory space and a computation time of O(li
3) per subject, with li as the number
of within subject measurements.
In our model setting, we defined Ki = e
−ρ2(tij−tij′ ) with a fixed ρ2 parameter. This
means Ki can be pre-computed before starting posterior sampling using MCMC. Further-
more, we propose using the eigenvalue decomposition technique for a faster log-posterior
probability computation. Our proposed method was motivated by Flaxman et al. (2015)
and is as follows.
Consider the covariance matrix κi
2Ki + σ
2Ili×li in the marginal log-density in equation
(23). Our goal is now to propose a method that makes computation of the inverse and the
determinant of this covariance function as efficient as possible. As shown earlier, Ki can
be pre-computed before starting the MCMC process as it does not involve any parameter.
Consider the eigenvalue decomposition of Ki = QΛQ
T , where Λ is a diagonal matrix with
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the eigenvalues of Ki as the diagonal elements, and Q is the corresponding matrix of
eigenvectors. κi
2 is a scalar parameter that is sampled in each iteration of the MCMC.
Multiplication of κi
2 times the matrix Ki implies the eigenvalues of this matrix will be
κi
2 times bigger where the eigenvectors remain the same. Hence, we can conclude that
the eigenvalue decomposition of the matrix κi
2Ki is of the form κi
2Ki = Q(κi
2Λ)QT ,
where Q and Λ are elements of the eigenvalue decomposition of the pre-computed matrix
Ki. Given the pre-computed eigenvalue decomposition of the matrix Ki, at each iteration
of the MCMC, the determinant of the covariance function of the marginal log-density in
equation (23) can be computed as
log|κi2Ki + σ2Ili×li | = log|Q(κi2Λ)QT + σ2Ili×li |
= log|Q(κi2Λ + σ2Ili×li)QT |
= log
( li∏
k=1
(κi
2λik + σ
2)
)
=
li∑
k=1
log
(
κi
2λik + σ
2
)
. (24)
In equation (24), λik’s are pre-computed eigenvalues of the matrix Ki whereas κi and σ
2
are parameters sampled at each iteration of the MCMC.
Similarly and by using the same trick, we can compute the term (Xi − β(L)i0 )T (κi2Ki +
σ2Ili×li)(Xi − β(L)i0 ) in a more computationally efficient as
(Xi − β(L)i0 )T (κi2Ki + σ2Ili×li)−1(Xi − β(L)i0 ) = (Xi − β(L)i0 )T
(
Q(κi
2Λ)QT + σ2Ili×li
)−1
(Xi − β(L)i0 )
= (Xi − β(L)i0 )T
(
Q(κi
2Λ + σ2Ili×li)Q
T
)−1
(Xi − β(L)i0 )
= (Xi − β(L)i0 )T
(
Q(κi
2Λ + σ2Ili×li)
−1QT
)
(Xi − β(L)i0 ).
(25)
In equation (25), Xi is the data matrix and is fixed, Q and Λ are pre-computed eigenvector
and diagonal eigenvalue matrices corresponding to the eigenvalue decomposition of the
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matrix Ki. Finally, by utilizing an eigenvalue decomposition, instead of evaluating the
term (κi
2Ki + σ
2Ili×li)
−1, one can simply evaluate
(
Q(κi
2Λ + σ2Ili×li)
−1QT
)
, where the
term (κi
2Λ + σ2Ili×li)
−1 in the middle is simply the inverse of a diagonal matrix.
3.2 Evaluation of the Survival Likelihood
Here we consider evaluation of the survival component of the decomposed joint likelihood.
Consider the survival time for subject i that is denoted by ti and is distributed according
to a Weibull distribution with shape parameter τ and scale parameter exp(λi), where
λi = ζ
(S)Z
(S)
i + ζ
(L)Z
(L)
i (t), where Z
(S)
i and Z
(L)
i (t) are vectors of covariates for subject i,
with potentially time-varying covariates, corresponding to the survival and the longitudinal
covariates respectively, and ζ(S) and ζ(L) are vectors of survival and longitudinal coefficients
respectively. One can write the hazard function hi(t) as
hi(t) = τt
τ−1exp(λi − exp(λi)tτ ). (26)
The survival function Si(t) can be written as
Si(t) = exp{−
∫ t
0
hi(w)dw}.
Consider survival data on n subjects, some of whom may have been censored. Let event
indicator δi that is 1 if the event is observed, and 0 otherwise. The survival likelihood
contribution of subject i can be written in terms of the the hazard function hi(t) and the
survival function Si(t) as
f
(i)
S|L = hi(ti)
δiSi(ti)
= hi(ti)
δie−
∫ ti
0 hi(w)dw.
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The overall survival log-likelihood can be written as
log(L) =
n∑
i=1
log(f
(i)
S|L)
=
n∑
i=1
(
δilog(hi(ti))−
∫ ti
0
hi(w)dw
)
.
The hazard function in the equation (26) includes some time-varying covariates which often
makes the integral of the hazard function non-tractable. In this case, one can estimate the
integral using the rectangular integration as follows:
Algorithm 1 *
Integration of Survival Hazard with Time-Varying Covariates
1. Set a fixed number of rectangles m and set A = 0
2. Divide (0, ti) interval into m equal pieces each of length L = ti/m
for i ∈ {1, . . . ,m} do
tmid ← L/2 + (i− 1) ∗ L
Atemp ← L ∗ hi(tmid)
A← A+ Atemp
end for
4 Simulation Studies
In this section, we evaluate our proposed models using a simulation study. We simulated 200
datasets that resembled the real data on end stage renal disease patients that was obtained
from the United States Renal Data System (USRDS). To this end, we first simulated
longitudinal trajectories with κ2’s which are sampled from a uniform distribution from 0 to
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1. We fixed ρ2 = 0.1 for all subjects. The subject-specific intercepts for albumin trajectories
were randomly sampled from the Normal distribution N(µ = 5.0, σ2 = 0.5). We simulate
9 to 12 longitudinal albumin values per subject. Using the simulated albumin trajectories,
we generated survival times from the Weibull distribution in equation (10) that is of the
following form for each of the proposed models
• Model I:
Ti|τ, β1, Xi(t) ∼ Weibull(τ, λi = β(s)i0 + β1Xi(t)), (27)
• Model II:
Ti|τ, β1, Xi(t) ∼ Weibull(τ, λi = β(s)i0 + β1Xi(t) + β2X ′AUC,i(t)), (28)
• Model III:
Ti|τ, β1, Xi(t) ∼ Weibull(τ, λi = β(s)i0 + β1Gender + β2β0(L) + β3κi2). (29)
The true values of the coefficients are set as follows
• model I: β1 = −0.5,
• model II: β1 = 0.5,
• model III: β1 = 0.5,
where in all simulations, β
(s)
i0 are simulated from a mixture of two Normal distributions
of the form θiN(µ = −1.5, σ2 = 1) + (1 − θi)N(µ = 1.5, σ2 = 1), where θi is distributed
Bernoulli with parameter p = 0.5.
Finally, the censoring times were sampled from a uniform distribution and indepen-
dently from the simulated event times with an overall censoring rate of 20%.
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All results are from 200 simulated datasets of size n = 300 subjects each. For each
dataset, we fit our proposed joint models with 10,000 draws where the first 5,000 considered
as a burn-in period. Relatively diffuse priors were considered for all parameters. Details of
the priors used in the simulations ass well as the results are as follow.
4.1 Simulation Results for Model I
In order to compare our proposed joint longitudinal-survival model that is capable of flexi-
bly modeling longitudinal trajectories with simpler models with explicit functional assump-
tions on the longitudinal trajectories, we simulated longitudinal data once from quadratic
polynomial longitudinal trajectory curves and another time from random non-linear curves.
We then fit our joint model with a Gaussian Process longitudinal component as well as
a joint model with the explicit assumption that the longitudinal trajectories are from a
quadratic polynomial curve. As a comparison model, we also fit a two-stage Cox model
where in stage one longitudinal data are modeled using our proposed Gaussian process
longitudinal model and in the second stage, given the posterior mean parameters from the
longitudinal fit, a Cox proportional hazard will fit the survival data.
In particular, we generate synthetic longitudinal and survival data on 300 subjects, each
with 9 to 12 within subject longitudinal albumin measures. Under the scenario where the
longitudinal data are generated from quadratic polynomial longitudinal trajectories, we
consider quadratic polynomial curves of the form
Xij = β
(L)
0i + β1it+ β2t
2 + ij,
where the true value of β0i are simulated from the Normal distribution N(µ = 5, σ
2 = 1),
β1i are simulated from the Normal distribution N(µ = −0.5, σ2 = 0.01), β2 is set to be
equal to -0.1, and finally ij is the measurement error that is independent across measures
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and across subjects and are simulated from the Normal distribution N(µ = 0, σ = 0.1).
Under the second scenario, longitudinal albumin values are generated from random
non-linear curves. In particular, we generate random non-linear albumin trajectories that
are realizations of a Gaussian process that are centered around the subject-specific random
intercepts β
(L)
0i that are generated from the Normal distribution N(µ = 5, σ
2 = 1). We
consider a Gaussian process with the squared exponential covariance function with the
correlation length of ρ2 = 0.1 and the subject-specific measures of volatility κ2i that are
generated from the uniform distribution U(0, 1).
For each simulation scenario, once longitudinal measures are generated, we generate
survival data where survival times are distributed according to the Weibull distribution
Weibull(τ, λi), where the shape parameter τ is set to 1.5 and λi, which is the log of the
scale parameter of the Weibull distribution, is set to β
(S)
i0 +β1Xi(t), where β
(S)
i0 are generated
from an equally weighted mixture of two Normal distributions of N(µ = −1.5, σ2 = 1) and
N(µ = 1.5, σ2 = 1), β1 is fixed to -0.5, and Xi(t) is the longitudinal value for subject i at
time t that is already simulated in the longitudinal step of the data simulation.
Our proposed joint longitudinal-survival model assumes the Normal priorN(µ = 5, σ2 =
4) on the random intercepts βi0, the log-Normal prior log-Normal(−1, 2) on κ2i , the log-
Normal prior log-Normal(−1, 1) on σ2, the log-Normal prior log-Normal(0, 1) on τ , the
Normal prior N(µ = 0, σ2 = 25) on the survival shared intercept β0, the Normal prior
N(µ = 0, σ2 = 25) on the survival coefficient β1, the Gamma prior Γ(3, 3) on the concen-
tration parameter of the Dirichlet distribution, and the Normal prior N(µ = 0, σ2 = 25) as
the base distribution of the Dirichlet distribution.
As the results in Table 1 show, when data are simulated with a longitudinal trajectories
that are quadratic polynomial curves, the joint polynomial model performs better in terms
of estimating the albumin coefficient in the survival model with a smaller mean squared
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error compared to our proposed joint longitudinal-survival. In real world, however, the
true functional forms of the trajectories of the biomarkers are not known. Under a general
case where the biomarker trajectories can be any random non-linear curve (scenario 2), our
proposed joint model outperforms the joint polynomial model. Further, our joint modeling
framework that is capable of estimating differential subject-specific log baseline hazards
provides significantly better coefficient estimates compared to the proportional hazard Cox
model. Estimates under the Cox model are marginalized over all subjects and due to the
non-collapsibility aspect of this model (Struthers and Kalbfliesch, 1986; Martinussen and
Vansteelandt, 2013), coefficient estimates shrink toward 0.
Covariate of True Conditional Two-Stage Cox Joint Polynomial Model Joint Model
Interest Estimand Mean SD MSE Mean SD MSE Mean SD MSE
Scenario 1
Albumin(t) -0.5 -0.273 0.056 0.119 -0.495 0.019 0.003 -0.441 0.105 0.012
Scenario 2
Albumin(t) -0.5 -0.258 0.080 0.125 -0.380 0.080 0.034 -0.462 0.110 0.010
Table 1: Model I Simulation results - joint longitudinal-survival data were generated under
the simulation scenarios of one when longitudinal measures are sampled from the quadratic
polynomial trajectories (scenario 1) and another scenario when longitudinal measures are
sampled from random non-linear curves (scenario 2). Under each scenario, we fit three
models of a joint longitudinal-survival model with the assumption that longitudinal trajec-
tories are quadratic polynomial (Joint Polynomial Model), our proposed joint longitudinal-
survival with a flexible Gaussian process longitudinal component (Joint Model), and a
two-stage Cox proportional model with longitudinal trajectories with parameters that set
to the posterior mean of a Gaussian process longitudinal model that is fit separately.
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4.2 Simulation Results for Model II
In model II, not only do we adjust for the albumin value at time Yi, but we also adjust
for a weighted average slope of albumin from time τ1 = 0 up until the time τ2 = Yi, where
Yi is either the event time for subject i or is the time that the subject got censored. This
new model differentiates between the risk of death for a patient whose albumin value is
improving compared to another patient with the same albumin level whose albumin is
deteriorating. In particular, we consider weighted average slope of albumin once under the
weighting scheme of the form
Q(t) =
1
τ1 − τ0 ,
and another time under the weighting scheme of
Q(t) =
1, if t = Ti0, otherwise.
The first weighting scheme leads to the area under the derivative curve. The second weight-
ing scheme will result in a point-wise derivative of albumin at time Yi.
We generate synthetic data for 300 subjects each with 9 to 12 longitudinal measurements
where longitudinal albumin values are generated from a Gaussian process that is centered
around the subject-specific random intercepts β
(L)
0i which are generated from the Normal
distribution N(µ = 5, σ2 = 1). We consider a Gaussian process with the squared expo-
nential covariance function with the correlation length of ρ2 = 0.1 and the subject-specific
measures of volatility κ2i that are generated from the uniform distribution U(0, 1). Once
longitudinal measures are generated, we generate survival data where survival times are
distributed according to the Weibull distribution Weibull(τ, λi), where the shape parameter
τ is set to 1.5 and λi, which is the log of the scale parameter in Weibull distribution, is set
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to β
(S)
i0 +β1Xi(t)+β2X
′
AUC,i(t), where β
(S)
i0 are generated from an equally weighted mixture
of two Normal distributions of N(µ = −1.5, σ2 = 1) and N(µ = 1.5, σ2 = 1), β1 is fixed to
0.3, β2 is fixed to 0.5, Xi(t) is the longitudinal value for subject i at time t and X
′
AUC,i(t)
is the average slope of albumin.
Our proposed joint longitudinal-survival model assumes the Normal priorN(µ = 5, σ2 =
4) on the random intercepts βi0, the log-Normal prior log-Normal(−1, 2) on κ2i , the log-
Normal prior log-Normal(−1, 1) on σ2, the log-Normal prior log-Normal(0, 1) on τ , the
Normal prior N(µ = 0, σ2 = 25) on the survival shared intercept β0, the Normal prior
N(µ = 0, σ2 = 25) on the survival coefficient β1, the Normal prior N(µ = 0, σ
2 = 25) on
the survival coefficient β2, the Gamma prior Γ(3, 3) on the concentration parameter of the
Dirichlet distribution, and the Normal prior N(µ = 0, σ2 = 25) as the base distribution of
the Dirichlet distribution.
We fit our proposed joint longitudinal-survival model. As a comparison, we also fit
a two-stage Cox model where the longitudinal curve of albumin and its derivative curve
are estimated using hyper-parameters set as the posterior median of a Bayesian Gaussian
Process model. As we can see from table 2, our joint model provides closer estimates to
the coefficient values with a smaller mean squared error compared with the two-stage Cox
model. Our proposed model is capable of detecting differential subject-specific baseline
hazards whereas the Cox model is not capable of differentiating between subjects and
provides estimates that are marginalized across all subjects. Further, the simulation results
show the capability of our method in detecting the true underlying longitudinal curves and
the ability of our method on properly estimating the average derivative of those curves.
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4.3 Simulation Results for Model III
In model III, we test the association between the summary measures of the longitudinal
biomarker trajectories and the survival outcomes. In particular, we consider the relation be-
tween the summary measures of subject-specific random intercept β
(L)
i0 and subject-specific
measure of volatility κ2i and survival times.
We generate synthetic data for N = 300 subjects each with 9 to 12 longitudinal mea-
surements where longitudinal albumin values are generated from a Gaussian process that is
centered around the subject-specific random intercepts β
(L)
0i which are generated from the
Normal distribution N(µ = 5, σ = 1). We consider a Gaussian process with the squared
exponential covariance function with the correlation length of ρ2 = 0.1 and the subject-
specific measures of volatility κ2i that are generated from the uniform distribution U(0, 1).
Once longitudinal measures are generated, we generate survival data where survival times
are distributed according to the Weibull distribution Weibull(τ, λi), where the shape pa-
rameter τ is set to 1.5 and λi, which is the log of the scale parameter in Weibull distribution,
is set to β
(S)
i0 +β1Age+β2βi0
(L)+β3κ
2
i
(L)
, where β
(S)
i0 are generated from an equally weighted
mixture of two Normal distributions of N(µ = −1.5, σ2 = 1) and N(µ = 1.5, σ2 = 1), β1
is fixed to 0.5, β2 is fixed to -0.3, β3 is fixed to 0.7, Age is a standardized covariate that
is generated from the Normal distribution N(µ = 0, σ2 = 1), βi0
(L) is subject-specific ran-
dom intercepts of the longitudinal trajectories, and κ2i
(L)
are subject specific measure of
volatility of the longitudinal trajectories.
Our proposed joint longitudinal-survival model assumes the Normal priorN(µ = 5, σ2 =
4) on the random intercepts βi0, the log-Normal prior log-Normal(−1, 2) on κ2i , the log-
Normal prior log-Normal(−1, 1) on σ2, the log-Normal prior log-Normal(0, 1) on τ , the
Normal prior N(µ = 0, σ2 = 25) on the survival shared intercept β0, the Normal prior
N(µ = 0, σ2 = 25) on the survival coefficient β1, the Normal prior N(µ = 0, σ
2 = 25) on
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the survival coefficient β2, the Gamma prior Γ(3, 3) on the concentration parameter of the
Dirichlet distribution, and the Normal prior N(µ = 0, σ2 = 25) as the base distribution of
the Dirichlet distribution.
We fit our proposed joint survival-longitudinal model (model III) as well as a two-stage
Cox proportional hazard model as a comparison model. The two-stage Cox model is a
simple Cox proportional hazard model with covariate β
(L)
0i and κ
2
i
(L)
that are posterior
medians from a separate longitudinal Gaussian process model. As the results in Table
3 show, our proposed joint model provides closer estimates to the true coefficients that
also have significantly smaller mean squared error compared to the two-stage Cox model.
Our proposed joint model is capable of detecting the differential subject-specific baseline
hazards. Unlike our model, Cox model is blind to the subject-specific baseline hazards
and hence, provides coefficient estimates that are marginalized over all subjects. These
marginalized estimates from the Cox model shrink toward 0 as the Cox model with a
multiplicative hazard function is non-collapsible.
As one can see in the joint model results in Table 3, the coefficient estimate for κ2
(L)
is not as close to the true coefficient value compared with other coefficient estimates. This
is due to the fact that only 9 to 12 longitudinal measures per subject, there exists many
plausible κ2i
(L)
values that flexibly characterize the trajectory of the measured albumin val-
ues. This additional variability in plausible κ2i
(L)
values has caused the coefficient estimate
to shrink toward 0. Larger number of within subject longitudinal measures will provide
more precision in estimating the true underlying κ2i
(L)
and will lead to a coefficient estimate
closer to the true value. In order to confirm this fact, we simulated additional data once
with 36 within subject measures and another time with 72 within subject measures. Table
4 shows the results of fitting our proposed joint longitudinal-survival model to datasets
that include subjects with 9 to 12 within subject measurements, to datasets with subjects
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with 36 within subject measurements, and to datasets with subjects with 72 within subject
measurements. As the results show, with larger number of within subject measurements,
coefficient estimate for κ2i
(L)
is closer to the true value. This is due to the fact that with
larger number of within subject albumin measurements, there exists a stronger likelihood
to estimate the subject-specific volatility measures κ2i , and hence, there is less uncertainty
about the estimated value of volatility measures.
5 Application of the Proposed Joint Models to ESRD
In this section, we apply our proposed joint longitudinal-survival models to data on n =
1, 112 end stage renal disease patients participating in the Dialysis Morbidity and Mortality
Studies (DMMS) nutritional study that is obtained from the United States Renal Data
System. For every participating patient in the study, up to 12 albumin measurements were
taken uniformly over two years of followup. The presented analyses are restricted to only
the patients who had at least nine albumin measurements in order to provide sufficient
data for modeling the trajectory and the volatility of albumin. The censoring rate in the
data is at 43% over a maximal follow-up time of 4.5 years.
Using the same data, Fung et al. (2002) showed that both baseline albumin level and the
slope of albumin over time are significant predictors of mortality among ESRD patients.
While our models are capable of replicating Fung et al’s findings, our models are also
capable of:
• model 1: testing the association between albumin value at the time of death and the
risk of death
• model 2: testing the association between albumin value and an average derivative of
albumin up until time t and the risk of death.
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• model 3: Testing the association between risk of mortality and the two summary
measures of the baseline and the volatility of albumin measures
In order to adjust for other potential confounding factors, our proposed models also include
patient’s age, gender, race, smoking status, diabetes, an indicator of whether the patient
appeared malnourished at baseline, BMI at baseline, baseline cholesterol, and baseline sys-
tolic blood pressure. The adjusted covariates are consistent with those originally presented
in Fung et al. (2002).
Table 5 and Table 6 provide the results of fitting our proposed model I, Model II, and
Model III to the USRDS data. All joint models were run for 10,000 posterior samples
where the initial 5,000 samples are discarded as burn-in samples.
5.1 Results for Model I
We fit our proposed joint model I to the data. As a comparison model, we also fit as last-
observation carried forward (LOCF) Cox model. Table 5 shows the estimated coefficients
from both models. Between the two models, the estimated relative risk associated with all
time-invariant baseline survival covariates are similar between the two models. However,
the relative risk associated with every one unit decrement in serum albumin is much larger
under our proposed joint model compared to the last-observation carried forward Cox
model. This is quite expected as our model is capable of estimating subject-specific albumin
trajectories over time and is capable of accurately testing the association between albumin
value at time of death and risk of death. Unlike our model,the LOCF Cox model uses the
most recent albumin measure which in reality might be quite different than the albumin
value at the time of death. In both models, albumin is identified as a significant risk factor
of mortality. In particular, based on the results from our proposed joint Model I, it is
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estimated that every 1 g/dL decrement in albumin is associated with a 4.5 times higher
risk of death.
5.2 Results for Model II
Other than the albumin value at the time of death, the average slope of albumin over
time might also be a risk factor of mortality in end-stage renal disease patients. In our
proposed joint Model II, we also adjust for the area under the derivative curve of the
albumin trajectory from the time that the follow-up starts until the survival time which
is either the time of death or the censoring time. Table 6 shows the results from our
proposed model. Based on the results, every one g/dL decrement in albumin is associated
with 3.95 times higher risk of death. Also, higher average slope of albumin, that is every 1
g/dL/month increase in the average slope, is associated with 2.3 times higher risk of death.
This is consistent with Fung et al. (2002) results on the association between the slope of
albumin and the risk of death. Our proposed method is also capable of adjusting for the
local effect of the slope of albumin. For instance, instead of averaging the slope of the
follow-up time, one may only integrate over the 6 months prior to the time of death.
5.3 Results for Model III
Fung et al. (2002) showed that the baseline albumin and the slope of albumin over time
are two independent risk factors of mortality among the end-stage renal disease patients.
It is quite natural to hypothesize that the volatility of albumin could also be a risk factor
of mortality among these patients. In our proposed joint longitudinal-survival Model III,
we consider two summary measures of the trajectories of the longitudinal albumin values,
one the baseline albumin measures (β0i
(L)), and another the subject-specific volatility mea-
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sure of albumin (κ2i
(L)
). Table 6 also shows the results from our proposed Model III. The
results from our model confirms that the baseline serum albumin is a risk factor of mor-
tality. Further, the results from our model indicate that the volatility of albumin is also a
significant risk factor of mortality, where every one unit increase in κ2, which indicates a
higher volatility, is associated with 1.2 times higher risk of death. Figure 2 shows albumin
trajectories of 10 randomly sampled individuals.
6 Discussion
Monitoring the health of patients often involves recording risk factors over time. In such
situations, it is essential to evaluate the association between those longitudinal measure-
ments and survival outcome. To this end, joint longitudinal-survival models provide an
efficient inferential framework.
We proposed a joint longitudinal-survival framework that avoids some of the restric-
tive assumptions commonly used in the existing models. Further, our methods propose a
stronger link between longitudinal and survival data through an introduction of new ways
of adjusting for the biomarker value at time t, adjusting for the average derivative of the
biomarker over time, and moving beyond the first-order trend and accounting for volatility
of biomarker measures over time.
Our proposed method can be considered as an extension of the joint model proposed by
Brown and Ibrahim (2003) in that we use the same idea of dividing the joint likelihood into
a marginal longitudinal likelihood and conditional survival likelihood. However, instead of
fitting quadratic trajectories, we use a flexible longitudinal model based on the Gaussian
processes. Further, for the survival outcome, instead of assuming a piecewise exponential
model, we use a flexible survival model by incorporating the Dirichlet process mixture of
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Weibull distributions. Our proposed modeling framework is capable of modeling additional
summary measures of longitudinally measured biomarkers and relating them to the survival
outcome in a time-dependent fashion.
Despite its flexibility and novelty, our approach has some limitations. By using th
Bayesian non-parameteric Dirichlet process and the Gaussian process techniques, while
we provide a flexible modeling framework that avoids common distributional assumptions,
however, these techniques are generally not scalable when the number of subjects and the
number of within subject measurements increase. Furthermore, the survival component of
our model still relies on the proportional hazard assumption. In future, our modeling frame-
work can be extended to include a more general non-proportional hazard survival models
that can also include time-dependent coefficients inside the survival model. By using some
alternatives to the common MCMC techniques, including parallel-MCMC methods and
variational methods, our method can become more computationally efficient and scalable
for larger datasets.
Often times in monitoring the health of patients, multiple longitudinal risk factors
are measured. One can use our proposed modeling framework in this paper in order to
build a joint longitudinal-survival model with multiple longitudinal processes each process
modeled independently from other longitudinal processes. In reality, however, one expects
that patients longitudinal risk factors to be correlated. A methodology that is capable of
modeling multiple biomarkers simultaneously by taking the correlation between biomarkers
into account can be beneficial.
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Covariate of True Conditional Two-Stage Cox Joint Model
Interest Estimand Mean SD MSE Mean SD MSE
Case 1 - Uniform Weights
Albumin(t) 0.3 0.191 0.099 0.022 0.303 0.109 0.008
Area under the derivative curve(t) 0.5 0.346 0.179 0.053 0.449 0.188 0.030
Case 2 - Point-Wise Weights
Albumin(t) 0.3 0.142 0.095 0.033 0.261 0.104 0.009
d(Albumin(t))
dt
0.5 0.412 0.123 0.022 0.477 0.152 0.013
Table 2: Model II simulation results - joint longitudinal-survival data were generated for
300 subjects each with 9 to 12 within subject measurements where longitudinal albumin
values are generated from a Gaussian process that is centered around the subject-specific
random intercepts β
(L)
0i which are generated from the Normal distribution N(µ = 5, σ
2 = 1).
We consider a Gaussian process with the squared exponential covariance function with the
correlation length of ρ2 = 0.1 and the subject-specific measures of volatility κ2i that are
generated from the uniform distribution U(0, 1). Once longitudinal measures are generated,
we generate survival data where survival times are distributed according to the Weibull
distribution Weibull(τ, λi), where the shape parameter τ is set to 1.5 and λi, which is the
log of the scale parameter in Weibull distribution, is set to β
(S)
i0 + β1Xi(t) + β2X
′
AUC,i(t),
where β
(S)
i0 are generated from an equally weighted mixture of two Normal distributions
of N(µ = −1.5, σ2 = 1) and N(µ = 1.5, σ2 = 1), β1 is fixed to 0.3, β2 is fixed to 0.5,
Xi(t) is the longitudinal value for subject i at time t and X
′
AUC,i(t) is the average slope of
albumin. We fit our proposed joint longitudinal-survival model as well as a two-stage Cox
proportional hazard model as a the comparison model.
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Covariate of True Conditional Two-Stage Cox Joint Model
Interest Estimand Mean SD MSE Mean SD MSE
Age (scaled) 0.5 0.262 0.124 0.070 0.492 0.149 0.013
Baseline Albumin (β0i
(L)) -0.3 -0.141 0.118 0.040 -0.284 0.116 0.008
κ2i
(L)
0.7 0.414 0.212 0.127 0.595 0.271 0.042
Table 3: Model III simulation results - joint longitudinal-survival data were generated
for 300 subjects each with 9 to 12 longitudinal measurements where longitudinal albumin
values are generated from a Gaussian process that is centered around the subject-specific
random intercepts β
(L)
0i which are generated from the Normal distribution N(µ = 5, σ
2 =
1). We consider a Gaussian process with the squared exponential covariance function
with the correlation length of ρ2 = 0.1 and the subject-specific measures of volatility κ2i
that are generated from the uniform distribution U(0, 1). Once longitudinal measures are
generated, we generate survival data where survival times are distributed according to
the Weibull distribution Weibull(τ, λi), where the shape parameter τ is set to 1.5 and λi,
which is the log of the scale parameter in Weibull distribution, is set to β
(S)
i0 + β1Age +
β2βi0
(L)+β3κ
2
i
(L)
, where β
(S)
i0 are generated from an equally weighted mixture of two Normal
distributions of N(µ = −1.5, σ2 = 1) and N(µ = 1.5, σ2 = 1), β1 is fixed to 0.5, β2 is fixed
to -0.3, β3 is fixed to 0.7, Age is a standardized covariate that is generated from the
Normal distribution N(µ = 0, σ2 = 1), βi0
(L) are subject-specific random intercepts of
the longitudinal trajectories, and κ2i
(L)
are subject specific measures of volatility of the
longitudinal trajectories. We fit our proposed joint longitudinal-survival model as well as
a two-stage Cox proportional hazard model as a the comparison model.
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Covariate of True Conditional Joint Model (li = 12) Joint Model (li = 36) Joint Model (li = 72)
Interest Estimand Mean SD MSE Mean SD MSE Mean SD MSE
Age (scaled) 0.5 0.492 0.149 0.013 0.493 0.144 0.015 0.495 0.145 0.016
βi0
(L) -0.3 -0.284 0.116 0.008 -0.308 0.116 0.006 -0.295 0.115 0.007
κ2i
(L)
0.7 0.595 0.271 0.042 0.639 0.284 0.043 0.651 0.293 0.039
Table 4: Model III simulation results with datasets with li = 36 and li = 72 within
subject measurements. In order to test the sensitivity of the κ2
(L)
coefficient estimate to
the number of within subject measurements, li, we simulated joint longitudinal-survival
data once when each subject has 36 within subject measurements and another time when
each subject has 72 within subject measurements. Under each scenario, we simulated 200
datasets each with 300 subjects. Other simulation parameters remained the same as the
simulation parameters used in Table 3. This means, we simulated longitudinal data from
Gaussian process that is centered around the subject-specific random intercepts β
(L)
0i which
are generated from the Normal distribution N(µ = 5, σ2 = 1). We consider a Gaussian
process with the squared exponential covariance function with the correlation length of ρ2 =
0.1 and the subject-specific measures of volatility κ2i that are generated from the uniform
distribution U(0, 1). Once longitudinal measures are generated, we generate survival data
where survival times are distributed according to the Weibull distribution Weibull(τ, λi),
where the shape parameter τ is set to 1.5 and λi, which is the log of the scale parameter in
Weibull distribution, is set to β
(S)
i0 + β1Age + β2βi0
(L) + β3κ
2
i
(L)
, where β
(S)
i0 are generated
from an equally weighted mixture of two Normal distributions of N(µ = −1.5, σ2 = 1)
and N(µ = 1.5, σ2 = 1), β1 is fixed to 0.5, β2 is fixed to -0.3, β3 is fixed to 0.7, Age is a
standardized covariate that is generated from the Normal distribution N(µ = 0, σ2 = 1),
βi0
(L) are subject-specific random intercepts of the longitudinal trajectories, and κ2i
(L)
are
subject specific measures of volatility of the longitudinal trajectories.
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LOCF Cox Model Joint Model
No. of No. of Relative Risk Relative Risk
Covariates Cases Deaths (95% CI) P-Value (95% CR)
Age (10y) 1,112 630 1.44 (1.35-1.53) <.001 1.45 (1.36,1.55)
Sex
Men 560 312 1.0 1.0
Women 552 318 0.96 (0.81,1.13) 0.60 0.97 (0.82,1.16)
Race
White 542 350 1.0 1.0
Black 482 243 0.81 (0.68,0.96) 0.01 0.79 (0.67,0.94)
Other 88 37 0.52 (0.37,0.74) <.001 0.49 (0.34,0.69)
Smoking
Nonsmoker 645 337 1.0 1.0
Former 307 197 1.17 (0.98,1.41) 0.09 1.20 (0.99,1.44)
Current 160 96 1.52 (1.19,1.94) <.001 1.53 (1.21,1.95)
Diabetes
No 716 363 1.0 1.0
Yes 396 267 1.66 (1.40,1.97) <.001 1.69 (1.43,2.00)
Undernourished
No 958 517 1.0 1.0
Yes 154 113 1.39 (1.12,1.72) 0.003 1.35 (1.08,1.66)
BMI (per-5 kg/m2
decrement) 1,112 630 1.08 (1.00,1.17) 0.07 1.08 (1.00,1.17)
Cholesterol (per 20
mg/dL) 1,112 630 0.97 (0.93,1.00) 0.08 0.96 (0.93,1.00)
Systolic blood pressure
(per 10mm Hg) 1,112 630 0.98 (0.95,1.02) 0.38 0.98 (0.95,1.02)
Serum albumin(t) (1-g/dL decrement) 1,112 630 2.48 (2.00,3.07) <0.001 4.54 (3.03,5.55)
Table 5: Estimated Relative Risk and corresponding 95% credible region from our proposed
joint model where we adjust for time-dependent albumin value that is imputed from the
longitudinal component of the model. We also fit a last-observation carried forward Cox
proportional hazards model with last albumin value carried forward where we report co-
efficients estimates, 95% confidence interval, and p-value for the estimated coefficients. In
both models, we adjust for potential confounding factors as reported by Fung et al. (2002).
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Joint Model
No. of No. of Relative Risk
Covariates Cases Deaths (95% CI)
Model 2
Serum Albumin(t) (1-g/dL decrement) 1,112 630 3.95 (3.18,4.71)
Average Derivative of Serum Albumin1 (1-g/dL/month decrement) 1,112 630 2.33 (1.40,3.73)
Model 3
Baseline Albumin(β0i
(L)) (1-g/dL decrement) 1,112 630 5.54 (4.19,6.94)
κ2i
(L)
(increase in volatility)2 1,112 630 1.23 (1.02,1.41)
1 : One may only consider the local effect of average serum albumin slope by computing the area under the
derivative from 6 months prior to death up until the time of death.
2 : In a similar model, we adjusted for κ2 values as a categorical variable with a cut point equal to the
posterior mean of all κ2 values (0.1) and we got a similar estimate relative risk (1.21).
Table 6: Model II and Model III results that show the estimated relative risk and corre-
sponding confidence intervals from our proposed joint model II and model III. Potential
confounding factors, as reported by Fung et al. (2002), were also adjusted in the model but
have been removed from the tables for brevity. Our proposed Model II is capable of testing
the association between albumin values at the time of death as well as the average deriva-
tive of the subject-specific albumin trajectories from the time the follow up time starts up
until the death or the censoring time. Our proposed Model III tests the association risk
of mortality and two albumin trajectory summary measures of the subject-specific random
intercepts (β0i
(L)) and the subject specific volatility measures (κ2i
(L)
).
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Figure 2: Actual longitudinal albumin trajectories of 10 randomly selected individuals
with end-stage renal disease that were selected from the USRDS data. Hollow circles are
the actual measured albumin values, red lines are the posterior median fitted curves from
our proposed Model III, and the dashed blue lines are the corresponding 95% posterior
prediction intervals for the fitted trajectories. The title of each plot shows the posterior
median of the volatility measure κ2 for the subject whose albumin measures are shown in
the plot.
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